红曲类制剂临床研究进展

摘要/Abstract

摘要： 红曲米是中国传统中药,近代研究发现红曲米内含有莫奈克林-K（Monaclin K）,其具有降低血脂作用,由此研发的他汀类药物在降低血脂、延缓及逆转动脉粥样硬化斑块,防治心血管病起到明显作用,并被国内外各类指南推荐。正是由于他汀类药物在临床的有效使用,引起对含有莫奈克林-K的红曲类制剂的关注和研究。本文收集红曲类制剂,包括药品和保健食品相关的临床研究文献,并对其临床试验研究的有效性、安全性及使用注意事项进行综述,为红曲米制剂的使用提供参考。

关键词: 他汀, 红曲米, 动脉粥样硬化

Abstract: Red yeast rice(RYR) is a traditional Chinese medicine. Modern studies have found that Monaclin K contains RYR, which has the effect of lowering blood lipids. Therefore, statins developed and developed have played an obvious role in reducing blood lipids, reversing and delaying atherosclerotic plaques, and preventing and treating cardiovascular diseases, and have been recommended by various domestic and foreign guidelines. It is because of the effective use of statins that attention and research have been paid to RYR containing Monaclin K. In this paper, clinical research literatures related to RYR preparations, including drugs and health care foods, were collected, and the effectiveness, safety and precautions of clinical trials were reviewed, so as to provide reference for the use of red yeast rice preparations.

Key words: statins, Red yeast rice, atherosclerosis

中图分类号:

R741
R285.5

于逢春, 毕齐. 红曲类制剂临床研究进展[J]. 中华养生保健, 2024, 42(17): 71-75.

YU Feng-Chun, Bi Qi. Progress of Clinical Research on Red Yeast Rice（RYR）[J]. ZHONGHUA YANGSHENG BAOJIAN, 2024, 42(17): 71-75.

参考文献

[1] 蒋沅岐,董玉洁,周福军,等.红曲的化学成分、药理作用及临床应用研究进展[J].中草药,2021,52(23):7379-7388.
[2] 张木兰,李淼.红曲”成分-药理-中药功效-疾病”研究进展及关联分析[J].亚太传统医药,2022,18(9):215-220.
[3] ENDO A, KURODA M, TSUJITA Y.ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogensis produced by Penicillium citrinum[J]. J Antibiot,1976,29(12):1346-1348.
[4] ENDO A.Monacolin K, a new hypocholesterolemic agent produced by a Monascus species[J]. J ANTIBIOT.,1979,32(8):852-854.
[5] 郭宗儒. 首创的洛伐他汀和后继药物[J].药学学报,2015,50(1):123-126.
[6] 夏玲红,孙黎,王玉洪,等.血脂康临床应用研究进展[J].医药导报,2018(A1):3.
[7] 中国老年学和老年医学学会心脑血管病专业委员会,血脂康(胶囊)临床应用中国专家共识组.血脂康(胶囊)临床应用中国专家共识(2017修订版)[J].中华内科杂志,2018,57(2):97-100.
[8] 中国心脏联盟,中国康复医学会心脏预防与康复专业委员会,脂必泰胶囊临床应用中国专家共识组.脂必泰胶囊临床应用中国专家共识[J].中华内科杂志,2017,56(8):628-632.
[9] 中国血脂管理指南修订联合专家委员.中国血脂管理指南(2023年)[J].中国循环杂志2023,38(3):237-271.
[10] 段俊超,李岚.从强化他汀到大剂量血脂康的临床研究进展[J].中国医药科学,2021,11(9):36-39,50.
[11] 蒋沅岐,董玉洁,周福军,等.红曲的化学成分、药理作用及临床应用研究进展[J].中草药,2021,52(23):7379-7388.
[12] 国家食品药品监督管理局.《关于以红曲等为原料保健食品产品申报与审评有关事项的通知》,国食药监许[2010]第2号[EB/OL].(2010-01-11)[2024-03-09].http://www.gov.cn/gzdt/2010-01/11/content_1507641.htm.
[13] 王琼,莫中成,郑标,等.红曲抗动脉粥样硬化的研究进展[J].湘南学院学报:医学版,2022(3):024.
[14] MINAMIZUKA T, KOSHIZAKA M, SHOJI M, et al.Low dose red yeast rice with monacolin K lowers LDL cholesterol and blood pressure in Japanese with mild dyslipidemia: A multicenter, randomized trial[J]. Asia Pacac J Clin Nutr,2021,30(3):424-435.
[15] RAHMANI P, MELEKOGLU E, TAVAKOLI S, et al.Impact of red yeast rice supplementation on lipid profile: a systematic review and meta-analysis of randomized-controlled trials[J]. Expert Rev Clin Phar,2022,16(1): 73-81.
[16] SUNGTHONG B, YOOTHAEKOOL C, PROMPHAMORN S, et al.Efficacy of red yeast rice extract on myocardial infarction patients with borderline hypercholesterolemia: A meta-analysis of randomized controlled trials[J]. Sci Rep,2020,10(1):2769.
[17] CICERO A F G, COLLETTI A, BAJRAKTARI G, et al. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel[J]. Arch Med Sci,2017,13(5):965-1005.
[18] 北京神经内科学会.纳豆激酶在血管病危险人群应用专家建议(2020版)[J].中国老年保健医学,2022,20(1):3-8.
[19] CHEN H, CHEN J, ZHANG F, et al.Corrigendum: Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: A clinical study with 1,062 participants[J]. Front Cardiovasc Med,2022,9:1076420.
[20] 慕琦,向凌云,赵艳岭,等.纳豆红曲胶囊活性成分及其保健功能研究进展[J].河南科学,2018,36(10):1562-1568.
[21] 齐明明,张文萌,印书霞,等.纳豆红曲复合物的降脂作用及药代动力学分析[J].现代食品科技,2021,37(12):1-6,56.
[22] 于逢春,周洋,张新宇,等.生活方式控制联合纳豆红曲胶囊降低血脂的临床研究[J].中华养生保健,2024,42(4):15-17,21.
[23] MAZZANTI G, MORO P A, RASCHI E, et al.Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system[J]. Brit J Clin Pharmaco,2017,83(4): 894-908.
[24] BARBACKI A, FALLAVOLLITA S A, KARMCHANDANI J, et al.Immune-Mediated Necrotizing Myopathy and Dietary Sources of Statins[J].Ann Intern Med,2018,168(12):893-904.
[25] FOGACCI F, BANACH M, MIKHAILIDIS D P, et al.Safety of red yeast rice supplementation: A systematic review and meta-analysis of randomized controlled trials[J]. Pharmacol Res,2019,143:1-16.
[26] 韩卓君,史胜楠,王培利.红曲米制剂调节心血管疾病风险人群血脂的系统评价与Meta分析[J].环球中医药,2022,15(2):229-238.
[27] 《动脉粥样硬化性心血管疾病患者降胆固醇药物治疗管理专家共识》编写组.动脉粥样硬化性心血管疾病患者降胆固醇药物治疗管理专家共识[J].临床药物治疗杂志,2023,21(2):7-16.
[28] VISSEREN, F L J, MACH F, SMULDERS Y M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice[J]. Eur Heart J,2021,42(34):3227-3337.
[29] BANACH M, CATAPANO A L, CICERO A F G, et al. Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel[J]. Pharmacol Res, 2022,183:106370.
[30] KIRKPATRICK C F, SIKAND G, PETERSEN, K S, et al.Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association[J]. J Clin Lipidol,2023,17(4):428-451.